Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug

ACT Capital Management acquired 174,250 ALMS shares in the first quarter, an estimated $4.36 million position based on average first-quarter pricing. The filing is a routine ownership update and does not indicate any operational change at the company. The news is mildly relevant for tracking investor positioning but is unlikely to materially move the stock on its own.

Analysis

ACT Capital Management acquired 174,250 ALMS shares in the first quarter, an estimated $4.36 million position based on average first-quarter pricing. The filing is a routine ownership update and does not indicate any operational change at the company. The news is mildly relevant for tracking investor positioning but is unlikely to materially move the stock on its own.